ALX Oncology Q1 net loss $30.2M ($0.74/sh); cash $256.2M; evorpacept trials advance

ALX ONCOLOGY HOLDINGS INC

2023-Q1 EPS reported -$0.74

GAAP net loss $30.2M vs $24.5M YoY; non-GAAP net loss $23.8M vs $19.0M.
Cash, equivalents and investments $256.2M; runway through mid-2025 with $40M term loan available.
R&D expenses $24.8M, up 45% YoY driven by more active trials and manufacturing.
Entered clinical collaboration with Sanofi to test evorpacept + SARCLISA in relapsed/refractory multiple myeloma.
Top-line data expected H2 2023 from ASPEN-06 (gastric cancer) and ASPEN-02 (MDS) trials.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ALX ONCOLOGY HOLDINGS INC reported financial results for first quarter ended March 31, 2023.

Period: first quarter ended March 31, 2023
Result: reported results

Exact text from the filing

On May 11, 2023, ALX Oncology Holdings Inc. (the "Company"), issued a press release announcing its financial results for the first quarter ended March 31, 2023.

View on SEC.gov

Browse all earnings releases →

ALX ONCOLOGY HOLDINGS INC filing history →

Source: SEC EDGAR

accession 0000950170-23-021199

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.